Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy improves glycemic control
In plain terms: Does testosterone therapy help blood sugar or diabetes?
Part of: 💊 Testosterone therapy (TRT)
It's contested. One major trial (T4DM) found testosterone plus lifestyle changes reduced progression to diabetes, but that study used men with only mildly low testosterone plus a lifestyle program — and other solid trials found no blood-sugar benefit. Guidelines advise against using testosterone purely to treat diabetes.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
TRT's effect on blood sugar and insulin resistance is contested. The landmark T4DM trial found testosterone plus a lifestyle program cut progression to type 2 diabetes — an impressive result — and one meta-analysis reports improved HbA1c and HOMA-IR. But other well-run RCTs (Grossmann, Magnussen) and the large TestES individual-patient meta-analysis found no meaningful glycemic benefit.
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Grossmann M, Hoermann R, Wittert G, Yeap BB 2015 · Clin Endocrinol (Oxf) | meta-analysis | tested-null | moderate | SR/MA of 7 placebo-controlled double-blind RCTs, 833 men with type 2 diabetes and/or metabolic syndrome. HbA1c, the claim's glycemic-control endpoint: MD -0.15% (95% CI -0.39 to 0.10, P=0.25) - point estimate toward improvement, interval includes zero: underpowered trend, graded tested-null per CONVENTIONS §5 second clarification (was mixed, but no result on glycemic control points against the claim). Insulin resistance split by equation: HOMA1 MD -1.58 (CI -2.25 to -0.91, P<0.001) vs HOMA2 MD -0.19 (CI -0.86 to 0.49, P=0.58) - an insulin-resistance surrogate, not glycemic control. Per-outcome trial counts not given in the abstract. Authors: does not support routine use without classical hypogonadism. |
| Magnussen LV 2016 · Diabetes Obes Metab | RCT | contradicts | moderate | RCT (aging T2DM): TRT did NOT improve insulin resistance or glycemic control; improved lean mass but reduced HDL. |
| Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH 2007 · Eur J Endocrinol | RCT | mixed | low | Crossover RCT (n=20): reduced leptin/waist; no significant effect on inflammatory markers (CRP, IL-6, TNF). |
| Griffith A, Perlman A, Karr T, Thompson ME, Kolterman O 2025 · Frontiers in endocrinology | observational | mixed | low | Single 52-year-old male on TRT for age-related testosterone decline had HbA1c fall from 7.2% to 5.9% at 3 months. Effect is confounded: co-delivered with enhanced lifestyle intervention and a 5-strain probiotic plus other supplements, so te |
| Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, BLAST Study Group 2014 · J Sex Med | RCT | supports | moderate | BLAST RCT (T2DM): significantly reduced HbA1c, waist, weight; effect blunted in men with comorbid depression. |
| Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT, Hague W, Jenkins A, Daniel M, Gebski V, Keech A 2021 · Lancet Diabetes Endocrinol | RCT | supports | high | T4DM (n=1007): TRT + lifestyle cut 2-yr progression to T2DM vs lifestyle alone (RR 0.59); greater 2-h OGTT glucose reduction. |
| Majumdar S, Mukherjee JJ, Ray S, Goswami S, Jude E, Biswas A, Hanumanthu A, John M, Sinha B, Ghoshal S, Kota S, Sharma SK, Jacob JJ 2021 · Diabetes Metab Syndr | mechanism | contradicts | low | IDEA consensus: recommends AGAINST TRT in T2DM men with only borderline-low T and no true hypogonadism. |
| Cruickshank M, Hudson J, Hernández R, Aceves-Martins M, Quinton R, Gillies K, Aucott LS, Kennedy C, Manson P, Oliver N, Wu F, Bhattacharya S, Dhillo WS, Jayasena CN, Brazzelli M 2024 · Nat Med | meta-analysis | contradicts | high | IPD meta 35 trials: no adverse glycemic effect but no meaningful glycemic improvement across trials overall. |
| Rastrelli G, Filippi S, Sforza A, Maggi M, Corona G 2018 · Sex Med Rev | mechanism | supports | low | Review: low T predicts incident metabolic syndrome and vice versa; T improves some components but authors flag 'not conclusive'. |
| Li SY, Zhao YL, Yang YF, Wang X, Nie M, Wu XY, Mao JF 2020 · Endocr J | meta-analysis | supports | moderate | Meta 18 RCTs (n=1415): reduced HbA1c (MD -0.67) and HOMA-IR (SMD -1.94); reduced LDL, triglycerides, weight, waist. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.